OLYMPIA-2: A phase 3 trial of odronextamab in people with relapsed or refractory follicular lymphoma
This trial aims to test the medication odronextamab when given with chemotherapy in people with previously untreated follicular lymphoma (FL).
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06097364
Trial aim and background
The aim of this trial is to assess the effectiveness and safety of the medication odronextamab when given with chemotherapy in patients with previously untreated FL.
Participants in this trial will either receive odronextamab in combination with chemotherapy, or rituximab and chemotherapy which is the current standard-of-care.
The trial will be in three parts:
- Part 1A and 1B: The aim is to see how safe and well tolerated odronextamab is when used with chemotherapy, and to establish a dose and dosing schedule.
- Part 2: The aim is to see how well it works compared to the current standard-of-care treatment regimen.
Who can enter
Adults with grade 1-3a FL who have not received any previous treatment may be eligible for this trial.
Locations
Recruitment is taking place at the following UK locations:
- Aberdeen Royal Infirmary, Aberdeen
- Royal Cornwall Hospitals NHS Trust, Truro
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06097364
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.